A working list of startups operating across Florida, with ecosystem organizations available as separate views. Search, sort, filter — submit additions anytime.
32 of 1504
#Company↑SectorStageFoundedDescriptionRegion
001
Adze Biotechnology
Adze Biotechnology is a pre-clinical stage company that develops oncolytic immunotherapies for the treatment of cancers. It has exclusive licenses to oncolytic immunotherapies developed in the lab of Dr. Michael Barry of Mayo Clinic. The company was founded in 2019 and is based in Coral Gables, Florida.
Biotechnology—2019Adze Biotechnology is a pre-clinical stage company that develops oncolytic immunotherapies for the treatment of cancers. It has exclusive licenses to oncolytic immunotherapies developed in the lab of Dr. Michael Barry of Mayo Clinic. The company was founded in 2019 and is based in Coral Gables, Florida.MIA→
002
Ambulero
Ambulero, Inc is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease.
Biotechnology—2019Ambulero, Inc is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease.MIA→
003
Ascend Advanced Therapies
Ascend helps make and sell gene therapy treatments. We know a lot about how to create and share these special medicines.
Biotechnology—2022Ascend helps make and sell gene therapy treatments. We know a lot about how to create and share these special medicines.GNV→
004
ASP Isotopes
ASP Isotopes is a pre-commercial stage advanced materials company that develops isotope enrichment technology for the medical, green energy, and industrial sectors
Biotechnology—2021ASP Isotopes is a pre-commercial stage advanced materials company that develops isotope enrichment technology for the medical, green energy, and industrial sectorsMIA→
005
Beacon Therapeutics
Beacon Therapeutics is a biotechnology firm in the clinical stage focused on preserving and enhancing vision for individuals affected by both uncommon and widespread eye disorders. The organization is leveraging the revolutionary potential of gene therapy to achieve significant results for serious eye conditions. Currently, Beacon's pipeline is aimed at severe retinal diseases that cause blindness, including X-linked retinitis pigmentosa (XLRP) and geographic atrophy.
Biotechnology—2023Beacon Therapeutics is a biotechnology firm in the clinical stage focused on preserving and enhancing vision for individuals affected by both uncommon and widespread eye disorders. The organization is leveraging the revolutionary potential of gene therapy to achieve significant results for serious eye conditions. Currently, Beacon's pipeline is aimed at severe retinal diseases that cause blindness, including X-linked retinitis pigmentosa (XLRP) and geographic atrophy.GNV→
006
Betaliq
Betaliq is a collaboration between Novaliq, GMBH, and BLP Management Group, LLC. It was formed to develop ophthalmic beta-blockers using Novaliq’s patented EyeSol non-water formulation technology. The company is developing two beta-blockers, for the treatment of glaucoma. BTQ 1901 is an EyeSol based formulation of a potent selective beta-blocker that has not previously been used to treat glaucoma. BTQ 1902 is an EyeSol based formulation of timolol, the most commonly prescribed beta-blockers.
Biotechnology—2018Betaliq is a collaboration between Novaliq, GMBH, and BLP Management Group, LLC. It was formed to develop ophthalmic beta-blockers using Novaliq’s patented EyeSol non-water formulation technology. The company is developing two beta-blockers, for the treatment of glaucoma. BTQ 1901 is an EyeSol based formulation of a potent selective beta-blocker that has not previously been used to treat glaucoma. BTQ 1902 is an EyeSol based formulation of timolol, the most commonly prescribed beta-blockers.TPA→
007
CellVax Therapeutics Inc.
CellVax Therapeutics is a privately-held clinical-stage company developing autologous anticancer vaccines
Biotechnology—2020CellVax Therapeutics is a privately-held clinical-stage company developing autologous anticancer vaccinesMIA→
008
Continuity Biosciences
Continuity Biosciences is a biotech business. The business is focused on developing and commercializing innovative drug delivery technologies, with a special emphasis on cell reprogramming, immune regulation, and ultra-long-acting delivery systems.
Biotechnology—2023Continuity Biosciences is a biotech business. The business is focused on developing and commercializing innovative drug delivery technologies, with a special emphasis on cell reprogramming, immune regulation, and ultra-long-acting delivery systems.SWFL→
009
Disruption Labs
Disruption Labs core strategy is a B2B business model, working in partnership with multi-national corporations and high-growth SMEs in the functional food & beverage and clinical therapeutic markets to improve or bio-enhance existing products areas, or create entirely new disruptive products. Disruption Labs performs R&D, including pharmacokinetic studies, to demonstrate product safety and improved efficacy, facilitating new product development from the lab bench top to product scale-up through market - offering a true end-to-end solution. In instance in which these strategic partnerships are not available, Disruption Labs plans to launch its own niche branded products, with R&D performed in-house to develop, scale-up and tech transfer, to bring to market scientifically validated, cutting-edge bio-enhanced product lines employing the proven, proprietary nanotechnology platform. Currently, Disruption Labs has developed a nano-liposomal CBD water soluble formulation, which utilizes its proprietary proven nanotechnology platform. The product is now sold under the brand Reset Bioscience, is currently being scientifically tested and validated for pharmacokinetic properties and manufactured under GMP-compliant conditions. Reset Biosciences has launched its first bio-enhanced, pharmaceutical grade, nano-liposomal product RESET Balance Jan 2019. More on RESET RESET Bioscience, a CBD and advanced wellness company, is the first to use pharmaceutical grade ingredients, and processes, for its pioneering CBD product. After extensive research, testing and validation the company is launching its debut product - RESET Balance, a 99.9% nano liposomal organic hemp CBD that compliments the body’s existing endocannabinoid system. The type of advanced nanotechnology used to produce this product uses liposomes as the trojan horse of drug delivery, providing approximately a 80% absorption/CBD effect at the cellular level, the highest in the industry today. With a commitment to quality, RESET Bioscience has spent $2M to double test for purity and efficacy, to introduce a product that will work as hard as you do to “reset” you to your baseline managing everyday stressors, including pain, anxiety, insomnia and more. RESET Balance is available in two flavors, neutral and peppermint, and is power packed with 300mg of organic triple tested CBD isolate, the most researched form of CBD on the market today, and importantly, with 0% THC. A unique attribute to RESET Balance is that it is white in color, due to the purity of the pharmaceutical grade lipids used. RESET has committed to self-regulate its developmental process, which means more safety and quality control measures have been taken to test and deliver a product that achieves real results, setting a new standard for CBD bioavailability through its proprietary nano liposomal delivery system.
Biotechnology—2017Disruption Labs core strategy is a B2B business model, working in partnership with multi-national corporations and high-growth SMEs in the functional food & beverage and clinical therapeutic markets to improve or bio-enhance existing products areas, or create entirely new disruptive products. Disruption Labs performs R&D, including pharmacokinetic studies, to demonstrate product safety and improved efficacy, facilitating new product development from the lab bench top to product scale-up through market - offering a true end-to-end solution. In instance in which these strategic partnerships are not available, Disruption Labs plans to launch its own niche branded products, with R&D performed in-house to develop, scale-up and tech transfer, to bring to market scientifically validated, cutting-edge bio-enhanced product lines employing the proven, proprietary nanotechnology platform. Currently, Disruption Labs has developed a nano-liposomal CBD water soluble formulation, which utilizes its proprietary proven nanotechnology platform. The product is now sold under the brand Reset Bioscience, is currently being scientifically tested and validated for pharmacokinetic properties and manufactured under GMP-compliant conditions. Reset Biosciences has launched its first bio-enhanced, pharmaceutical grade, nano-liposomal product RESET Balance Jan 2019. More on RESET RESET Bioscience, a CBD and advanced wellness company, is the first to use pharmaceutical grade ingredients, and processes, for its pioneering CBD product. After extensive research, testing and validation the company is launching its debut product - RESET Balance, a 99.9% nano liposomal organic hemp CBD that compliments the body’s existing endocannabinoid system. The type of advanced nanotechnology used to produce this product uses liposomes as the trojan horse of drug delivery, providing approximately a 80% absorption/CBD effect at the cellular level, the highest in the industry today. With a commitment to quality, RESET Bioscience has spent $2M to double test for purity and efficacy, to introduce a product that will work as hard as you do to “reset” you to your baseline managing everyday stressors, including pain, anxiety, insomnia and more. RESET Balance is available in two flavors, neutral and peppermint, and is power packed with 300mg of organic triple tested CBD isolate, the most researched form of CBD on the market today, and importantly, with 0% THC. A unique attribute to RESET Balance is that it is white in color, due to the purity of the pharmaceutical grade lipids used. RESET has committed to self-regulate its developmental process, which means more safety and quality control measures have been taken to test and deliver a product that achieves real results, setting a new standard for CBD bioavailability through its proprietary nano liposomal delivery system.TPA→
010
Empowered Diagnostics
Empowered Diagnostics delivers innovative diagnostic tests backed by experts in healthcare and biotechnology. The company is driven by a mission to empower people with the knowledge and confidence to understand their health through reliable, affordable, high-quality tests.
Biotechnology—2017Empowered Diagnostics delivers innovative diagnostic tests backed by experts in healthcare and biotechnology. The company is driven by a mission to empower people with the knowledge and confidence to understand their health through reliable, affordable, high-quality tests.MIA→
011
Gibson Oncology
Gibson Oncology acquired the Indenos to provide a noticeable positive impact on cancer patient’s lives in two critical areas. First, cancer resistance continues to emerge among almost all cancer patients whom initially responded to some form of treatment. Indenos were specifically designed to achieve high drug concentrations and remain within cancer cells for optimal anti-cancer activity, which reduces the chances that cancer cells’ can remove the anti-cancer drug to avoid its own destruction – thus, Indenos fight cancer resistance. Second, Indenos have a favorable side effect profile so that cancer patients experience a better quality of life during treatment with no grade 3 or 4 diarrhea and much less grade 3 and 4 neutropenia. They believe, therefore, that their goal of Being Tough on Cancer, not on Patients, can be achieved through these novel anti-cancer drugs, and their planned Phase II trials are well-positioned for treating resistant cancers in children and adults.
Biotechnology—2018Gibson Oncology acquired the Indenos to provide a noticeable positive impact on cancer patient’s lives in two critical areas. First, cancer resistance continues to emerge among almost all cancer patients whom initially responded to some form of treatment. Indenos were specifically designed to achieve high drug concentrations and remain within cancer cells for optimal anti-cancer activity, which reduces the chances that cancer cells’ can remove the anti-cancer drug to avoid its own destruction – thus, Indenos fight cancer resistance. Second, Indenos have a favorable side effect profile so that cancer patients experience a better quality of life during treatment with no grade 3 or 4 diarrhea and much less grade 3 and 4 neutropenia. They believe, therefore, that their goal of Being Tough on Cancer, not on Patients, can be achieved through these novel anti-cancer drugs, and their planned Phase II trials are well-positioned for treating resistant cancers in children and adults.MIA→
012
Gradian Diagnostics
Gradian Diagnostics is a biotechnology company that focuses on developing Next-Gen medical and diagnostics technologies. Its philosophy is to take a practical approach to develop its portfolio. The company believes that inspiration must always be backed up by a heavy dose of quantitative evidence and apply hard-nosed management fundamentals to ensure science actually turns into commercially successful products that make a the difference in the lives of patients. The company was founded in 2018 and is headquartered in Miami Beach, Florida.
Biotechnology—2018Gradian Diagnostics is a biotechnology company that focuses on developing Next-Gen medical and diagnostics technologies. Its philosophy is to take a practical approach to develop its portfolio. The company believes that inspiration must always be backed up by a heavy dose of quantitative evidence and apply hard-nosed management fundamentals to ensure science actually turns into commercially successful products that make a the difference in the lives of patients. The company was founded in 2018 and is headquartered in Miami Beach, Florida.MIA→
013
HCW Biologics
HCW Biologics is developing immunotherapies to lengthen healthspan by disrupting the link between cellular senescence and disease.
Biotechnology—2018HCW Biologics is developing immunotherapies to lengthen healthspan by disrupting the link between cellular senescence and disease.PAN→
014
Imaginostics
Imaginostics is a health tech company developing a quantitative vascular MRI platform (ImagiView™) and AI-powered biomarker engine (ImagiSight™) that transforms standard MRI scanners into precision diagnostic instruments — no new hardware required. From a single scan on existing MRI systems, the platform generates individual-patient maps of microvascular density, blood-brain barrier permeability, and vessel structure. Lead indications include malignant brain neoplasm and Alzheimer's disease. Imaginostics holds FDA Breakthrough Device Designation and a letter of support from Siemens Healthineers, and is backed by the NIH and the Alzheimer's Drug Discovery Foundation.
Biotechnology—2018Imaginostics is a health tech company developing a quantitative vascular MRI platform (ImagiView™) and AI-powered biomarker engine (ImagiSight™) that transforms standard MRI scanners into precision diagnostic instruments — no new hardware required. From a single scan on existing MRI systems, the platform generates individual-patient maps of microvascular density, blood-brain barrier permeability, and vessel structure. Lead indications include malignant brain neoplasm and Alzheimer's disease. Imaginostics holds FDA Breakthrough Device Designation and a letter of support from Siemens Healthineers, and is backed by the NIH and the Alzheimer's Drug Discovery Foundation.ORL→
015
ImmunoProfile
ImmunoProfile is a biotechnology company that focuses on manufacturing diagnostic kits for multiple therapeutic areas.
Biotechnology—2018ImmunoProfile is a biotechnology company that focuses on manufacturing diagnostic kits for multiple therapeutic areas.SWFL→
016
Inflammx Therapeutics
Inflammx Therapeutics is a biotechnology startup company. It was founded in Tampa, Florida in 2020.
Biotechnology—2020Inflammx Therapeutics is a biotechnology startup company. It was founded in Tampa, Florida in 2020.TPA→
017
Innovative Genetics
Innovative Genetics is building the infrastructure layer behind the next wave of compliant therapeutics. We develop and license BioIP—fast-acting formulations, nationally trademarked brand systems, compliant packaging, and deployable production infrastructure—designed for scale, structured for recurring revenue, and protected by intellectual property. Our model is entirely non-substance-touching, enabling operators in legal U.S. markets to commercialize without federal exposure or capital-heavy overhead. We generate revenue through licensing, royalties, and infrastructure leasing—without cultivation, manufacturing, or retail.
Biotechnology—2017Innovative Genetics is building the infrastructure layer behind the next wave of compliant therapeutics. We develop and license BioIP—fast-acting formulations, nationally trademarked brand systems, compliant packaging, and deployable production infrastructure—designed for scale, structured for recurring revenue, and protected by intellectual property. Our model is entirely non-substance-touching, enabling operators in legal U.S. markets to commercialize without federal exposure or capital-heavy overhead. We generate revenue through licensing, royalties, and infrastructure leasing—without cultivation, manufacturing, or retail.MIA→
018
Ki Health
Kihealth is poised to revolutionize diabetes care with the launch of the world's first blood test capable of identifying diabetes risk before symptoms emerge. This innovative point-of-care and at-home diagnostic test developed at Yale University is set to become the new standard of care in adolescent screening and emerge as a crucial instrument in early detection for type 2 diabetes.
Biotechnology—2023Kihealth is poised to revolutionize diabetes care with the launch of the world's first blood test capable of identifying diabetes risk before symptoms emerge. This innovative point-of-care and at-home diagnostic test developed at Yale University is set to become the new standard of care in adolescent screening and emerge as a crucial instrument in early detection for type 2 diabetes.JAX→
019
Lacerta Therapeutics
Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, Lacerta Therapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.
Biotechnology—2017Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, Lacerta Therapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.GNV→
020
Marizyme
Marizyme is a development-stage company dedicated to the commercialization of therapies that address the urgent need for higher mortality and costs in the acute care space. The company's first product candidates are derived from a broad intellectual property portfolio around a novel system of proteolytic enzymes called ProteomeX (previously referred to as Krillase Technology). Marizyme completed the acquisition of these assets and intends to immediately develop several product candidates that will address unmet medical needs in the acute care setting.
Biotechnology—2018Marizyme is a development-stage company dedicated to the commercialization of therapies that address the urgent need for higher mortality and costs in the acute care space. The company's first product candidates are derived from a broad intellectual property portfolio around a novel system of proteolytic enzymes called ProteomeX (previously referred to as Krillase Technology). Marizyme completed the acquisition of these assets and intends to immediately develop several product candidates that will address unmet medical needs in the acute care setting.MIA→
021
Method Testing Labs
Method Testing Labs provides tools to cultivate, manufacture, and distribute hemp or cannabis products. The company's team is composed of researchers, chemists, pharmaceutical scientists, and former industry leaders in the cannabis and hemp industry. Method Testing Labs was founded in 2019 by Rob Radke and is headquartered in Tampa, Florida, United States.
Biotechnology—2019Method Testing Labs provides tools to cultivate, manufacture, and distribute hemp or cannabis products. The company's team is composed of researchers, chemists, pharmaceutical scientists, and former industry leaders in the cannabis and hemp industry. Method Testing Labs was founded in 2019 by Rob Radke and is headquartered in Tampa, Florida, United States.TPA→
022
Myosin Therapeutics
Myosin Therapeutics is a privately-held biopharmaceutical company developing novel medications for CNS-based disorders. The company specializes in molecular machines that turn energy into mechanical work inside cells, enabling doctors to treat various disease states, including cancer, and focuses on developing innovative drugs that target cellular motor proteins.
Biotechnology—2020Myosin Therapeutics is a privately-held biopharmaceutical company developing novel medications for CNS-based disorders. The company specializes in molecular machines that turn energy into mechanical work inside cells, enabling doctors to treat various disease states, including cancer, and focuses on developing innovative drugs that target cellular motor proteins.MIA→
023
NAYA Biosciences
NAYA Biosciences is an agile and synergistic platform that provides access to the next generation of biotechnologies, increasing patient access to life-changing medicines in oncology, fertility, and regenerative medicine.
Biotechnology—2023NAYA Biosciences is an agile and synergistic platform that provides access to the next generation of biotechnologies, increasing patient access to life-changing medicines in oncology, fertility, and regenerative medicine.SWFL→
024
Nomax Therapeutics
Nomax Therapeutics develops a healthcare technology platform to provide therapies for neurodegenerative diseases. It focuses on life sciences, discoveries in physics and chemistry, and products with no harmful side effects that help patients to restore stability of the body and ensure normal brain functions. The company was founded in 2021 and is headquartered in North Miami Beach, Florida.
Biotechnology—2021Nomax Therapeutics develops a healthcare technology platform to provide therapies for neurodegenerative diseases. It focuses on life sciences, discoveries in physics and chemistry, and products with no harmful side effects that help patients to restore stability of the body and ensure normal brain functions. The company was founded in 2021 and is headquartered in North Miami Beach, Florida.MIA→
025
Nula Therapeutics
Nula Therapeutics pioneering a new class of medicines to treat metabolic dysfunction, neurodegeneration, and cancer.
Biotechnology—2021Nula Therapeutics pioneering a new class of medicines to treat metabolic dysfunction, neurodegeneration, and cancer.TPA→